Learn about high cholesterol and plaque buildup. Take an interactive artery tour.

Description: This is a very elaborate site on the risks associated with high cholesterol and plaque buildup. It also is a comprehensive sales-pitch for Crestor. Whats new about this Crestor site is that it uses a form of augmented reality to educate people about high cholesterol and plaque buildup.

Click here to visit the site.

To see all of the ads from this campaign, click here

Brand name: Crestor
Generic name/category: Rosuvastatin, statins
Company: AstraZeneca
Country/Market: USA, North America
Indication(s)/use: high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia)
Target: Consumer (DTC)
Medium: Internet
Publication: 2009

To see all Crestor ads, click here

From Wikipedia:
Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Shionogi developed the product and the pharmaceutical company AstraZeneca markets it as Crestor.

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.

More on Wikipedia

Click here to see the details and full-size version of this ad on AdPharm

AdPharm is the largest online pharmaceutical advertising gallery. It is subscription-based with various subscriptions plans available here.

New indication
A new reason to treat with Revatio…

Revatio delays clinical worsening in patients with PAH (WHO Group I)

Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was developed and is being marketed by the pharmaceutical company Pfizer. It acts by inhibiting cGMP specific phosphodiesterase type 5, an enzyme that regulates blood flow in the penis. Since becoming available in 1998, sildenafil has been the prime treatment for erectile dysfunction; its primary competitors on the market are tadalafil (Cialis) and vardenafil (Levitra).

As well as erectile dysfunction, sildenafil citrate is also effective in the rare disease pulmonary arterial hypertension (PAH). It relaxes the arterial wall, leading to decreased pulmonary arterial resistance and pressure. This in turn reduces the workload of the right ventricle of the heart and improves symptoms of right-sided heart failure. Because PDE-5 is primarily distributed within the arterial wall smooth muscle of the lungs and penis, sildenafil acts selectively in both these areas without inducing vasodilation in other areas of the body. Pfizer submitted an additional registration for sildenafil to the FDA, and sildenafil was approved for this indication in June 2005. The preparation is named Revatio, to avoid confusion with Viagra, and the 20 milligram tablets are white and round. Sildenafil joins bosentan and prostacyclin-based therapies for this condition.

More on Wikipedia

Brand name: Revatio
Generic name/category: Sildenafil, PDE5 inhibitors, Citrates
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: Pulmonary Arterial Hypertension (PAH)
Target: Healthcare Professionals (HCP)
Tagline: Start with confidence
Medium: Print ad
Size/duration: three-page spread
Publication/Aired: Chest – August 2009

“Now that I know how plaque can build in my arteries, I'm ready to Take Action.”

Get a Take Action kit to learn about high cholesterol and plaque buildup in arteries -and discover how Crestor can help.

Sig up for a Take Action Kit and get a 30-day free trial offer for Crestor. Go to TakeAction.com today.

Rosuvastatin is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. Shionogi developed the product and the pharmaceutical company AstraZeneca markets it as Crestor.

Rosuvastatin is approved for the treatment of high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.

In 2008, research emerged that rosuvastatin could reduce the risk of heart attack, stroke, and other vascular complications in patients with elevated C-reactive protein but no other risk factors. This could strongly impact medical practice by placing many patients on statin prophylaxis that otherwise would have been untreated.

The results of the JUPITER trial suggested that rosuvastatin may decrease the relative risk of heart attack and stroke in patients without hyperlipidemia.

The AURORA trial randomized 2776 patients undergoing hemodialysis to receive either rosuvastatin or placebo. The randomized, double-blind study found no difference in the two groups in the primary end point, a combination of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The study found no difference in all-cause mortality among this population at a mean follow up of 3.8 years.

More on Wikipedia

Brand name: Crestor
Generic name/category: Rosuvastatin, statins
Company: AstraZeneca
Country/Market: USA, North America
Indication(s)/use: high LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia)
Target: Consumer (DTC)
Medium: Print ad
Size/duration: single-page plus one-third
Publication: Heart Healthy Living – Fall 2009

To see all Crestor ads, click here
1 views
Sep 07, 2009

Visit AdPharm.net for more pharmaceutical ads

OAB symptoms may cause patients to change their behavior.
Behavior change may help patients manage their OAB symptoms.
Discover a new OAB treatment option that comes with a free patient support plan.

Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. It is sold under the trade names Detrol and Detrusitol.

More on Wikipedia

Brand name: Pfizer Corporate
Generic name/category: Tolterodine, antimuscarinic, unbranded, teaser ad
Company: Pfizer
Country/Market: USA, North America
Indication(s)/use: urinary incontinence, Overactive Bladder (OAB)
Target: Healthcare Professionals (HCP)
Medium: Web banner
Size/duration: 300X250
Publication/Aired: Urology Times - September 9, 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads

“beautiful”
beautiful

Fast wrinkle removal
Jeternel beauty clinic
www.jeternel-lab.ru

Agency: Voskhod, Yekaterinburg, Russia
Creative Director: Andrey Gubaydullin
Art Director: Vladislav Derevynnykh
Copywriter: Evgeny Primachenko
Illustrator and Designer: Dmitry Maslakov

Brand name: Jeternel beauty clinic
Generic name/category: Beauty clinic, aesthetics, dermatology
Country/Market: Russia, Europe
Indication(s)/use: skin_care, wrinkle removal
Target: Consumers (DTC)
Tagline: Fast wrinkle removal
Medium: Print ad
Size/duration: single-page, poster
Publication/Aired: August 2009
Source: Ads of the World

To see all of the ads from this campaign, click here
4 views
Aug 26, 2009

Visit AdPharm.net for more pharmaceutical ads

attractive?
attractive

Fast wrinkle removal
Jeternel beauty clinic
www.jeternel-lab.ru

Agency: Voskhod, Yekaterinburg, Russia
Creative Director: Andrey Gubaydullin
Art Director: Vladislav Derevynnykh
Copywriter: Evgeny Primachenko
Illustrator and Designer: Dmitry Maslakov

Brand name: Jeternel beauty clinic
Generic name/category: Beauty clinic, aesthetics, dermatology
Country/Market: Russia, Europe
Indication(s)/use: skin_care, wrinkle removal
Target: Consumers (DTC)
Tagline: Fast wrinkle removal
Medium: Print ad
Size/duration: single-page, poster
Publication/Aired: August 2009
Source: Ads of the World

To see all of the ads from this campaign, click here
1 views
Aug 26, 2009

Visit AdPharm.net for more pharmaceutical ads